Press Releases + News Year: - Any -20252024202320222021202020192018201720162015201420132012201120102009 Items per page 102550 Date Title and Summary View Toggle SummaryAug 10, 2015 Galectin Therapeutics Provides Phase 2 NASH Program Update and Reports Second Quarter 2015 Financial Results View HTML Galectin Therapeutics Provides Phase 2 NASH Program Update and Reports Second Quarter 2015 Financial Results 24 KB Toggle SummaryJul 15, 2015 Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development View HTML Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development 23.6 KB Toggle SummaryJun 29, 2015 Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis First Five Patients Screened View HTML Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis 30.9 KB Toggle SummaryJun 03, 2015 Galectin Therapeutics Names Dr. Marc Rubin Lead Independent Director View HTML Galectin Therapeutics Names Dr. Marc Rubin Lead Independent Director 27.4 KB Toggle SummaryMay 28, 2015 Galectin Therapeutics to Present at LD Micro Invitational Conference View HTML Galectin Therapeutics to Present at LD Micro Invitational Conference 19.2 KB Toggle SummaryMay 15, 2015 Galectin Therapeutics to Webcast Corporate Update Following Annual Meeting of Stockholders View HTML Galectin Therapeutics to Webcast Corporate Update Following Annual Meeting of Stockholders 20.6 KB Toggle SummaryMay 14, 2015 Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam Phase 1 Pharmacokinetic Study Conducted in Accordance With FDA Requirements; Results Add to the GR-MD-02 Safety Profile and Allow for Expansion of Number of Patients Eligible to be Included in Phase 2 Clinical Trials View HTML Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam 18.9 KB Toggle SummaryMay 11, 2015 Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase 2 NASH Program View HTML Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase 2 NASH Program 34.8 KB Toggle SummaryMar 24, 2015 Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of Liver Diseases Industry Colloquium View HTML Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of Liver Diseases Industry Colloquium 19 KB Toggle SummaryMar 18, 2015 Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update View HTML Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update 32 KB Pagination First page First Previous page Previous … Page 21 Current page 22 Page 23 Page 24 … Next page Next Last page Last
Galectin Therapeutics Provides Phase 2 NASH Program Update and Reports Second Quarter 2015 Financial Results 24 KB
Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development 23.6 KB
Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis 30.9 KB
Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase 2 NASH Program 34.8 KB
Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of Liver Diseases Industry Colloquium 19 KB
